Acute generalized exanthematous pustulosis, usually called AGEP, is a rare and dramatic skin reaction in which dozens to hundreds of tiny pus-filled bumps erupt rapidly over reddened skin, most often triggered by a medication. It affects roughly one to five people per million per year, and while the rash itself looks alarming, AGEP resolves on its own in most cases within about two weeks once the offending drug is stopped.1PubMed Central. Acute Generalised Exanthematous Pustulosis: An Update The condition sits in a category of severe drug reactions alongside better-known names, but its speed of onset, distinctive appearance, and generally favorable prognosis set it apart in ways worth understanding.
What Triggers AGEP
Drugs are by far the leading cause. The most frequently implicated class is beta-lactam antibiotics, a group that includes penicillin, amoxicillin, and cephalosporins.2PubMed Central. Acute generalized exanthematous pustulosis induced by hydroxychloroquine: a case with atypical clinical presentation Other common culprits include macrolide antibiotics, antimalarials like hydroxychloroquine, antifungal agents, and calcium channel blockers. The list of medications reported to cause AGEP is long and continues to grow, partly because the condition was not widely recognized until the 1980s and case reports keep adding new drugs.
Not every case traces back to a pill. Infections, vaccinations, and even spider bites have all been documented as triggers.3PubMed Central. Acute Generalized Exanthematous Pustulosis: Clinical Features, Differential Diagnosis, and Management Viral infections are a particularly common trigger in children, with pathogens like Epstein-Barr virus, enterovirus, cytomegalovirus, and hepatitis B all implicated.4DermNet. Acute generalised exanthematous pustulosis In the case of spider bites, the venom contains an enzyme that stimulates the release of the same chemical messengers involved in AGEP, which helps explain how a bite could set off a pustular eruption that looks identical to a drug-triggered case.5PubMed. Acute generalized exanthematous pustulosis (AGEP) triggered by a spider bite
How the Rash Develops
AGEP typically begins within a few days of starting a new medication, though the lag can stretch to a couple of weeks. The first sign is usually a burning or itching sensation on the skin, quickly followed by widespread redness. Within hours, clusters of tiny non-follicular pustules appear on top of that red, swollen base. “Non-follicular” means the bumps do not center around hair follicles, which is one way clinicians distinguish AGEP from other pustular conditions. The pustules are small, often pinhead-sized, and can number in the hundreds, sometimes merging into larger sheets of pus.6PubMed Central. Acute Generalized Exanthematous Pustulosis: Pathogenesis, Genetic Background, Clinical Variants and Therapy
The rash usually starts in skin folds like the groin, armpits, and neck, then spreads outward to the trunk and limbs. Fever is almost always present and can be high. Blood tests at this stage often show a surge in white blood cells, especially neutrophils and eosinophils. In a U.S. cohort study, about 8% of patients had an acute rise in liver enzymes and a similar proportion developed kidney insufficiency during the episode.7JAMA Dermatology. Clinical Characteristics, Disease Course, and Outcomes of Patients With Acute Generalized Exanthematous Pustulosis in the US Systemic involvement beyond the skin occurs in roughly one in five cases overall.8PubMed Central. Acute Generalized Exanthematous Pustulosis: Pathogenesis, Genetic Background, Clinical Variants and Therapy
When AGEP Becomes Dangerous
Most cases resolve without lasting harm, but the rare severe presentation can be genuinely life-threatening. Case reports describe patients whose AGEP escalated to circulatory shock resembling sepsis, with blood-pressure collapse requiring vasopressor medications, kidney failure needing dialysis, and respiratory failure requiring intubation.9PubMed Central. Acute Generalized Exanthematous Pustulosis with Multiple Organ Failure One published case described a patient whose AGEP mimicked septic shock so convincingly that the initial clinical approach focused entirely on treating infection before the true cause was recognized.10BMJ Case Reports. Multisystem organ failure secondary to acute generalised exanthematous pustulosis AGEP with atypical presentation resembling septic shock
These severe outcomes are uncommon, but they underscore why AGEP is classified as a severe cutaneous adverse reaction. The overlap with sepsis is particularly dangerous because the two conditions share many clinical features, including fever, elevated white blood cell counts, and hemodynamic instability. A patient covered in pustules who is spiking a fever and whose blood pressure is dropping can easily be treated for a bacterial infection they do not have, which delays recognition that a drug reaction is the actual problem.
How Doctors Tell It Apart From Pustular Psoriasis
The condition AGEP is most easily confused with is generalized pustular psoriasis. Both produce widespread sterile pustules on red skin. Both cause fever and elevated neutrophils. From a distance, they can look identical. The distinction matters because treatment and prognosis differ substantially, and psoriasis is a chronic disease that requires a very different management approach.
Clinical history is the strongest initial clue. AGEP almost always follows drug exposure by days, while pustular psoriasis is more likely to occur in someone with a known history of psoriasis or to flare without a clear drug trigger. Skin biopsy helps refine the diagnosis further. Under the microscope, AGEP tends to show eosinophils mixed into the pustules and surrounding tissue, dead keratinocytes scattered through the skin layers, and spongiosis, which is a sponge-like swelling of the epidermis. Pustular psoriasis, by contrast, more often shows tortuous, dilated blood vessels and lacks the eosinophil-rich infiltrate.11PubMed. The histopathological spectrum of acute generalized exanthematous pustulosis (AGEP) and its differentiation from generalized pustular psoriasis A large study of 102 AGEP biopsies found eosinophils in the dermal infiltrate in about 81% of cases, with papillary edema in 88% and neutrophil-dominant infiltrates extending into the deeper dermis in 95%.12PubMed. The spectrum of histopathological features in acute generalized exanthematous pustulosis: a study of 102 cases
Even with biopsy, the overlap is real enough that an international scoring system, the EuroSCAR validation score, was developed specifically to help standardize the diagnosis. It weighs features like the speed of onset, the morphology and distribution of pustules, fever, blood counts, and histological findings to produce a probability score for AGEP. The system is imperfect but widely used, and a European expert consensus effort has sought to further refine diagnostic and management recommendations.13PubMed Central. Acute Generalized Exanthematous Pustulosis: Clinical Features, Differential Diagnosis, and Management
The Immune Mechanism Behind AGEP
AGEP is driven by T cells that react to a drug and release large amounts of a signaling protein called IL-8, which is a powerful magnet for neutrophils. Once those neutrophils flood into the skin, they cause the characteristic pustule formation. Researchers have confirmed this by isolating drug-specific T cells from the blood of AGEP patients; most of these T cells produce IL-8, which explains the massive neutrophil recruitment.14Dermatology. Acute Generalized Exanthematous Pustulosis: Clinical Characteristics, Pathogenesis, and Management
There is also a genetic dimension. Some patients carry mutations in a gene called IL36RN, which normally helps regulate a family of inflammatory signaling molecules. When this gene does not work properly, the inflammatory braking system is weakened, predisposing the person to excessive neutrophilic inflammation in the skin. IL36RN mutations have been found in patients with AGEP as well as in people with generalized pustular psoriasis and other pustular conditions, reinforcing the idea that these diseases share a common inflammatory pathway even though they differ in their triggers and course.15PubMed. The genetic background of generalized pustular psoriasis: IL36RN mutations and CARD14 gain-of-function variants A study of Chinese patients with various pustular skin diseases confirmed that IL36RN variants were strongly associated with AGEP and highlighted what the authors called the “IL-1/IL-36–chemokine–neutrophil axis” as a shared pathogenic mechanism across several pustular conditions.16Clinical and Experimental Dermatology. Genetic analysis of different subtypes of aseptic pustulosis in the Chinese population
Beyond IL36RN, certain HLA types, the molecules that help the immune system recognize foreign substances, have been linked to AGEP susceptibility in pharmacogenomic studies. Specific HLA alleles have been reported in individual case studies of drug-induced AGEP, though the evidence is still emerging and no single HLA type has been established as a universal risk marker.17PubMed Central. Hydroxychloroquine-induced acute generalized exanthematous pustulosis with HLA-typing
Identifying the Culprit Drug
Once AGEP is diagnosed, figuring out which drug caused it is often straightforward if the patient recently started one new medication. It gets much harder when multiple drugs were introduced around the same time, which happens frequently in hospitalized patients. Patch testing, where small amounts of suspected drugs are applied to the skin under adhesive patches and observed for a localized reaction, is one approach used after recovery. A literature review of patch testing in AGEP found the test’s sensitivity hovers around 50%, meaning it catches the guilty drug roughly half the time. Patch testing appears to be safe in recovered AGEP patients, though mild flares of skin symptoms can occasionally occur.18PubMed. Results of patch testing in acute generalized exanthematous pustulosis (AGEP): A literature review
A modified version of the lymphocyte transformation test, which measures how a patient’s T cells respond to a suspected drug in a lab dish, has shown promise as a complementary diagnostic tool. In a small validation study, the assay correctly matched clinical findings in most patients tested.19PubMed Central. Development and initial validation of a modified lymphocyte transformation test (LTT) assay in patients with DRESS and AGEP Neither test is perfect, so the clinical timeline, the known risk profile of each drug, and published case literature all factor into the final assessment of which medication to blame and which ones are safe to use again.
Treatment and Recovery
The single most important step is stopping the offending drug. In most patients, AGEP resolves spontaneously once the trigger is removed. The pustules dry up, and the affected skin peels off in characteristic small collarettes of flaking skin over the course of about ten days.20DermNet. Acute generalised exanthematous pustulosis Most patients recover fully within ten to fourteen days of drug withdrawal.21Prescriber Update. Acute generalised exanthematous pustulosis (AGEP)
Beyond drug cessation, treatment is supportive. Topical corticosteroids and emollients help with discomfort. Systemic corticosteroids are widely prescribed despite limited strong evidence of their effectiveness, and at least one study found their use was associated with a shorter hospital stay.22PubMed Central. Acute generalized exanthematous pustulosis: Epidemiology, clinical course, and treatment outcomes of patients treated in an Asian academic medical center In cases that do not respond adequately to corticosteroids, particularly those triggered by hydroxychloroquine which can be more protracted, cyclosporine has been used successfully as a second-line therapy.23PubMed. Cyclosporine for corticosteroid-refractory acute generalized exanthematous pustulosis due to hydroxychloroquine For the rare cases progressing to multi-organ involvement, intensive supportive care with fluids, vasopressors, and sometimes dialysis becomes necessary.
AGEP in Children
AGEP looks similar in children and adults, but the triggers differ in an important way. While drugs remain the most common cause overall, infections play a proportionally larger role in pediatric cases than in adults. A systematic review of 47 pediatric cases confirmed that medications were still the leading trigger, but infectious causes contributed at higher rates than reported in adult studies.24PubMed Central. A Systematic Review of Pediatric Acute Generalized Exanthematous Pustulosis A ten-year retrospective review from Singapore found that among eight children diagnosed with AGEP, all had an intercurrent illness, and five cases were attributed to infection rather than drugs.25PubMed. Acute generalized exanthematous pustulosis in children and adolescents in Singapore: A ten-year retrospective review
The good news is that outcomes in children are generally excellent. All pediatric patients in that Singapore series recovered, with acute pustulation lasting an average of about six days. None of the children had a personal or family history of psoriasis, and all developed the characteristic post-pustular skin peeling during recovery.26PubMed. Acute generalized exanthematous pustulosis in children and adolescents in Singapore: A ten-year retrospective review One child did have a recurrent episode, which is worth noting because recurrence is considered unusual in AGEP.
AGEP During Pregnancy
Pregnancy adds a layer of complexity to any severe drug reaction. AGEP has been reported in pregnant patients, and the cases illustrate both the stakes and the management challenges involved. In one reported case, a 30-year-old woman with lupus developed AGEP at 27 weeks of pregnancy after starting hydroxychloroquine. Despite stopping the drug, her skin lesions worsened and she required infliximab therapy. She subsequently developed a secondary chest infection related to her compromised skin barrier and immunosuppression, ultimately requiring prolonged antibiotics and an early cesarean delivery at 32 weeks.27Modern Rheumatology Case Reports. Initiation of hydroxychloroquine therapy during pregnancy can cause adverse effects and alter pregnancy outcomes
That case is notable because hydroxychloroquine is generally considered safe in pregnancy and current guidelines recommend it for lupus patients who are pregnant or planning to become pregnant. The authors emphasized that starting the drug before conception, rather than during pregnancy, is preferable to reduce the risk of complications if an adverse reaction does occur. A separate reported case had a more reassuring outcome: a pregnant woman who developed AGEP was treated with systemic methylprednisolone and topical steroids, her symptoms resolved, and she went on to deliver a healthy baby at full term without complications.28PubMed. Food-induced acute generalized exanthematous pustulosis in a pregnant woman
Why AGEP Gets Misdiagnosed
Several features of AGEP conspire to make it easy to miss or mislabel. The rash can overlap visually with drug-induced Stevens-Johnson syndrome in its early erythematous phase, with pustular psoriasis once the pustules are established, and with bacterial sepsis when the systemic features dominate. The high fever and neutrophilia that accompany AGEP routinely prompt empirical antibiotics, which adds irony to the situation since antibiotics are the most common trigger for the condition in the first place.
Part of the diagnostic difficulty is rarity itself. With only one to five cases per million people per year, many physicians will go their entire careers without seeing a case, which means AGEP may not appear high on anyone’s mental checklist when confronted with an acutely ill, febrile patient covered in pustules.29PubMed Central. Acute Generalised Exanthematous Pustulosis: An Update Dermatology consultation and skin biopsy are the most reliable path to the correct diagnosis, but in an emergency setting where a patient looks septic, a biopsy may not be the first priority.
The overlap with pustular psoriasis deserves special mention because early immunostaining research found no difference in a common cell-proliferation marker between AGEP and pustular psoriasis, meaning that particular test does not help distinguish the two.30PubMed. A comparison of Ki-67 antigen presentation in acute generalized exanthematous pustulosis and pustular psoriasis Clinicians rely instead on the combination of features already described: eosinophils, dead keratinocytes, the absence of dilated vessels, and the temporal relationship to a drug. Getting it right has real consequences, because a patient mislabeled with pustular psoriasis may be started on long-term immunosuppressive therapy they do not need, while a patient whose AGEP is missed may continue taking the drug that caused the reaction.